Story
Scribe Therapeutics IPO to Price at Top of Range Amid Strong Demand, Reports Say

Scribe Therapeutics Inc. is expected to price its initial public offering at the top of its indicated range of $13 to $15 per share, according to a Bloomberg News report citing people familiar with the matter.
Strong Investor Demand
The strong pricing is reportedly driven by robust interest from investors. The early-stage genetic medicines developer received demand for multiple times the number of available shares, particularly from anchor-type investors, the sources told Bloomberg.
The sources requested anonymity because the information has not been made public. A representative for Scribe Therapeutics did not immediately respond to a request for comment, according to the report.
AdMarket Implications
Pricing an IPO at the top of the marketed range is often a bullish signal, indicating strong investor confidence in a company's growth prospects and business model. For a clinical-stage company like Scribe, it suggests a healthy appetite in the public markets for high-risk, high-reward opportunities within the biotechnology sector.
A successful debut could also provide a positive data point for the broader IPO market, which is closely watched by private companies and investors considering public listings.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.